Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis

British Journal of Ophthalmology

Volumn 95, Issue 5, 2011, Pages 613-619

  Ferrari, Stefano ^a   Ponzin, Diego ^a   Ashworth, Jane L ^b   Fahnehjelm, Kristina Teär ^c,d   Summers, C Gail ^e   Harmatz, Paul R ^f   Scarpa, Maurizio ^g  

^a The Veneto Eye Bank Foundation   (Italy)

^b MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MINNESOTA   (United States)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; CORTICOSTEROID; GALSULFASE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; LARONIDASE; RECOMBINANT ENZYME;

ANTERIOR EYE SEGMENT; CATARACT; CLINICAL FEATURE; CORNEA NEOVASCULARIZATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ECHOOCULOGRAPHY; ELECTRORETINOGRAPHY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EYE DISEASE; GLAUCOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INTRAOCULAR HYPERTENSION; KERATOPLASTY; LAMELLAR KERATOPLASTY; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS; OPTIC NERVE ATROPHY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PENETRATING KERATOPLASTY; POSTERIOR EYE SEGMENT; PREVALENCE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SCHEIE SYNDROME; VISUAL SYSTEM EXAMINATION;

CORNEAL OPACITY; EYE DISEASES; FEMALE; GLAUCOMA; HUMANS; MALE; MUCOPOLYSACCHARIDOSES; OCULAR HYPERTENSION; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 79955007802     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.179937     Document Type: Review

References (82)

1. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995;72:263e7.
2. Ashworth JL, Biswas S, Wraith E, et al. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006;51:1e17.
3. Kenyon KR. Ocular manifestations and pathology of systemic mucopolysaccharidoses. Birth Defects Orig Artic Ser 1976;12:133e53.
4. Ashworth JL, Biswas S, Wraith E, et al. The ocular features of the mucopolysaccharidoses. Eye 2006;20:553e63.
5. Karageorgos L, Brooks DA, Pollard A, et al. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 2007;28:897e903.
6. Beesley CE, Meaney CA, Greenland G, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 2001;109:503e11.
7. Müller-Forell W, Schulze Frenking G, Amraoui Y, et al. Mucopolysaccharidoses (MPS). Clinical and neuroradiological aspects of the different types. Clin Neuroradiol 2007;17:141e58.
8. de Jong JGN, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 1992;38:803e7.
9. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011e17.
10. Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984e2004. Am J Med Genet A 2009;149A:960e4.
11. Nowaczyk MJ, Clarke JTR, Morin JD. Glaucoma as an early complication of Hurler's disease. Arch Dis Child 1988;63:1091e3.
12. Alroy J, Haskins M, Birk DE. Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI. Exp Eye Res 1999;68:523e30.
13. Summers CG, Whitley CB, Holland EJ, et al. Dense peripheral corneal clouding in Scheie syndrome. Cornea 1994;13:277e9.
14. Connell P, McCreery K, Doyle A, et al. Central corneal thickness and its relationship to intraocular pressure in mucopolysaccararidoses-1 following bone marrow transplantation. J AAPOS 2008;12:7e10.
15. Summers CG, Purple RL, Krivit W, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology 1989;96:977e85.
16. Martins AM, Dualibi AP, Norato D, et al. Guidelines for the management of mucopolysaccharidosis type I. J Pediatr 2009;155:S32e46.
17. Pastores GM, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab 2007;91:37e47.
18. Azevedo ACMM, Schwartz IV, Kalakun L, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 2004;66:208e13.
19. Collins MLZ, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 1990;97:1445e9.
20. Cantor LB, Disseler JA, Wilson FM II. Glaucoma in the MaroteauxeLamy syndrome. Am J Ophthalmol 1989;108:426e30.
21. Spellacy E, Bankes JLK, Crow J, et al. Glaucoma in a case of Hurler disease. Br J Ophthalmol 1980;64:773e8.
22. Quigley HA, Maumenee AE, Stark WJ. Acute glaucoma in systemic mucopolysaccharidosis I-S. Am J Ophthalmol 1975;80:70e2.
23. Mullaney P, Awad AH, Millar L. Glaucoma in mucopolysaccharidosis 1-H/S. J Pediatr Ophthalmol Strabismus 1996;33:127e31.
24. Sato S, Maeda N, Watanabe H, et al. Multiple iridociliary cysts in patients with mucopolysaccharidoses. Br J Ophthalmol 2002;86:933e4.
25. Schumacher RG, Brzezinska R, Schulze-Frenking G, et al. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008;38:543e50.
26. Vine AK. Uveal effusion in Hunter's syndrome. Evidence that abnormal sclera is responsible for the uveal effusion syndrome. Retina 1986;6:57e60.
27. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120:405e18.
28. Caruso RC, Kaiser-Kupfer MI, Muenzer J, et al. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology 1986;93:1612e16.
29. Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 1998;105:1099e105.
30. Tzetzi D, Hamilton R, Robinson PH, et al. Negative ERGs in mucopolysaccharidoses (MPS) HurlereScheie (I-H/S) and Hurler (I-H)-syndromes. Doc Ophthalmol 2007;114:153e8.
31. Anawis MA. Hunter syndrome (MPS II-B): a report of bilateral vitreous floaters and maculopathy. Ophthalmic Genet 2006;27:71e2.
32. Usui T, Shirakashi M, Takagi M, et al. Macular edema-like change and pseudopapilledema in a case of Scheie syndrome. J Clin Neuroophthalmol 1991;11:183e5.
33. Fahnehjelm KT, Törnquist AL, Winiarski J, et al. Ocular axial length and corneal refraction in children with mucopolysaccharidosis (MPS I-Hurler). Acta Ophthalmol. Published Online First: 10 June 2010. doi:10.1111/j.1755-3768. 2010.01934.x.
34. Fahnehjelm KT, Törnquist AL, Malm G, et al. Ocular findings in four children with mucopolysaccharidosis IeHurler (MPS I-H) treated early with haematopoietic stem cell transplantation. Acta Ophthalmol Scand 2006;84:781e5.
35. Pitz S, Ogun O, Bajbouj M, et al. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol 2007;125:1353e6.
36. Pitz S, Ogun O, Arash L, et al. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol 2009;247:975e80.
37. Tonnu PA, Ho T, Newson T, et al. The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry. Br J Ophthalmol 2005;89:851e4.
38. Francis BA, Hsieh A, Lai MY, et al. Effects of corneal thickness, corneal curvature, and intraocular pressure level on Goldmann applanation tonometry and dynamic contour tonometry. Ophthalmology 2007;114:20e6.
39. Lanzl IM, Leroy BP. Ocular features of treatable lysosomal storage disorders- Fabry disease, mucopolysaccharidoses I, II and VI and Gaucher disease. Eur Ophthalmic Rev 2008;2:55e62.
40. Yoon MK, Chen RW, Hedges TR III, et al. High-speed, ultrahigh resolution optical coherence tomography of the retina in Hunter syndrome. Ophthalmic Surg Lasers Imaging 2007;38:423e8.
41. Grupcheva CN, Craig JP, McGhee CNJ. In vivo microstructural analysis of the cornea in Scheie's syndrome. Cornea 2003;22:76e9.
42. Mocan MC, Eldem B, Irkec M. In vivo confocal microscopic findings of two siblings with MaroteauxeLamy syndrome. Cornea 2007;26:90e3.
43. Patel DV, Ku JYF, Kent-Smith B, et al. In vivo microstructural analysis of the cornea in MaroteauxeLamy syndrome. Cornea 2005;24:623e5.
44. Belani KG, Krivit W, Carpenter BLM, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993;28:403e8.
45. Walker RWM, Darowski M, Morris P, et al. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 1994;49:1078e84.
46. Sjøgren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand 1987;31:214e18.
47. Diaz JH, Belani KG. Perioperative management of children with mucopolysaccharidoses. Anesth Analg 1993;77:1261e70.
48. Pinello L, Busin M, Fontana L, et al. Application of (lamellar) keratoplasty and limbal stem cell transplantation for corneal clouding in the mucopolysaccharidosesda review. Clin Exp Ophthalmol 2010;38:52e62.
49. Nischal KK. Pediatric keratoplasty. Techniques in Ophthalmology 2003;1: 119e26.
50. Bergwerk K, Falk RE, Glasgow BJ, et al. Corneal transplantation in a patient with mucopolysaccharidosis type VII (Sly disease). Ophthalmic Genet 2000;21:17e20.
51. Käsmann-Kellner B, Weindler J, Pfau B, et al. Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and long-term results of perforating keratoplasty. Ophthalmologica 1999;213:200e5.
52. Varssano D, Cohen EJ, Nelson LB, et al. Corneal transplantation in MaroteauxeLamy syndrome. Arch Ophthalmol 1997;115:428e9.
53. Uçakhan ÖÖ, Brodie SE, Desnick R, et al. Long-term follow-up of corneal graft survival following bone marrow transplantation in the MaroteauxeLamy syndrome. CLAO J 2001;27:234e7.
54. Rosen DA, Edmison DR, Robertson DM. Five year maintenance of corneal graft normality in systemic mucopolysaccharidosis. Can J Ophthalmol 1972;7:445e53.
55. Naumann G. Clearing of cornea after perforating keratoplasty in mucopolysaccharidosis type VI (MaroteauxeLamy syndrome). N Engl J Med 1985;312:995. (Pubitemid 15111970)
56. Schwartz MF, Werblin TP, Green WR. Occurrence of mucopolysaccharide in corneal grafts in the MaroteauxeLamy syndrome. Cornea 1985;4:58e66.
57. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004;15:119e26.
58. Harmatz P. Entering a new treatment age for mucopolysaccharidosis VI disease: a search for better markers of disease progression and response to treatment. J Pediatr (Rio J) 2008;84:103e6.
59. Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123:19e29.
60. Gabrielli O, Clarke LA, Bruni S, et al. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010;125: e183e7.
61. McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age e a sibling control study. Clin Genet 2010;77:492e8.
62. Summers CG, Fahnehjelm KT, Pitz S, et al. Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapyda review. Clin Exp Ophthalmol 2010;38:34e42.
63. Fahnehjelm KT, Törnquist AL, Winiarski J. Dry-eye syndrome after allogeneic stemcell transplantation in children. Acta Ophthalmol 2008;86:253e8.
64. Fahnehjelm KT, Törnquist AL, Olsson M, et al. Visual outcome and cataract development after allogeneic stem-cell transplantation in children. Acta Ophthalmol Scand 2007;85:724e33.
65. Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006;38:17e21.
66. Wynn RF, Mercer J, Page J, et al. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr 2009;154:135e9.
67. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533e9.
68. Harmatz P, Giugliani R, Schwartz IVD, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4- sulfatase. Mol Genet Metab 2008;94:469e75.
69. Scarpa M, Barone R, Fiumara A, et al. Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 2009;168:1203e6.
70. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465e73.
71. Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123:229e40.
72. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-L-iduronidase (laronidase). J Pediatr 2004;144:581e8.
73. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005;6:489e506.
74. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182e8.
75. Koseoglu ST, Harmatz P, Turbeville S, et al. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy. Int Ophthalmol 2009;29:267e9.
76. Ponder KP, Haskins ME. Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 2007;7:1333e45.
77. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009;15:23e31.
78. Ponder KP, Auricchio A. Gene therapy for ocular problems in mucopolysaccharidosis: an experimental and promising approach with benefits in animal modelsda review. Clin Exp Ophthalmol 2010;38:43e51.
79. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231e9.
80. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979e90.
81. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240e8.
82. Ashworth JL, Kruse FE, Bachmann B, et al. Ocular manifestations in the mucopolysaccharidosesda review. Clin Exp Ophthalmolda review. 2010;38:12e22.